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bstract
Sulindac is an analgesic and anti-inflammatory agent. It has the general side-effects of non-steroidal anti-inflammatory drugs,
wing to presence of a free carboxylic acid group. The aim of the study was to retard the adverse gastrointestinal effects of the drug.
arious conjugates of sulindac were synthesized by amidation with methyl esters of 10 amino acids. The synthesized conjugates
ere characterized by melting-point, thin-layer chromatography and Fourier transform infrared, nuclear magnetic resonance and
ass spectroscopy. The synthesized conjugates were evaluated pharmacologically for analgesic, anti-inflammatory and ulcerogenic
ctivity. Amide conjugation had a synergistic potentiating effect, with less disruption of mucosal surfaces. This conjugate
pproach can therefore be used successfully to minimize gastrointestinal toxicity with no loss of the desired anti-inflammatory and
nalgesic activities of the drug. Methyl 2-(2-((7Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-inden-3-yl)acetamido)-
-phenylpropanoate and methyl 2-(2((6Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-inden-3-yl)acetamido)-3-
ethylbutanoate showed excellent pharmacological responses and encouraging hydrolysis rates in simulated gastric fluid,
imulated intestinal fluid and 80% human plasma. Conjugates with longer aliphatic side chains or aromatic substituents had
igher partition coefficients but lower dissolution and hydrolysis rates. These conjugates could be considered for sustained release
reparations.
 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1.  Introduction
Sulindac, {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulf-
inyl)benzylidene]-1H-indene-3-yl}acetic acid (Fig. 1),
is a non-steroidal anti-inflammatory drug (NSAID) of the
arylalkanoic acid class, which cannot be used optimallybehalf of Taibah University. This is an open access article under the
because of the adverse reactions due to the presence of
a free carboxylic acid group. The precise mechanism of
action of sulindac is unknown, but it is thought to act
on COX-1 and COX-2 enzymes to inhibit prostaglandin
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Fig. 1. Sulindac {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)
slowly to methanol (22 mL) with cooling, and amino acid
(0.005 mol/L) was added. The mixture was refluxed forbenzylidene]-1H-indene-3-yl}acetic acid.
synthesis. NSAIDs are widely used for indications ran-
ging from inflammation and pain to cardiovascular and
genitourinary diseases. Gastrointestinal effects are the
most frequent adverse reactions of NSAIDs, which often
lead to gastrointestinal ulceration and haemorrhage [1].
Gastrointestinal mucosal injury produced by NSAIDs
is generally considered to be due to two mechanisms,
the first involving a local action with direct contact
and the other an indirect effect on the gastrointestinal
mucosa. The direct effect can be attributed to a com-
bination of a local irritation produced by the acidic
group of NSAIDs and local inhibition of prostaglandin
synthesis in the gastrointestinal tract. The indirect
effect can be attributed to a combination of an ion-
trapping mechanism from the lumen into the mucosa,
which is a generalized systemic action occurring after
absorption, as demonstrated after intravenous dosing
[2,3].
Interest has focused on the development of bio-
reversible derivatives as a mean of reducing the
gastrointestinal toxicity, by temporary masking of the
acidic group of NSAIDs [4]. By the addition of various
amino acids—non-polar, polar, acidic and basic—the
drug can be made more or less polar or more or less sol-
uble in a given solvent. Amino acids contain both acidic
and basic groups and exist in the zwitterionic form. The
non-availability of a free amino group in the zwitterionic
form of an amino acid restricts its use in the formation
of amides. Esterification of amino acids in the pres-
ence of HCl produces amino acid ester hydrochloride,
and neutralization of HCl with aqueous alkali, pyri-
dine or triethylamine generates a free amino group to
react as a nucleophile in the synthesis of amide [5].
The aim of the study reported here was to synthesize
and characterize amino acid conjugates of sulindac with
the expectation of obtaining nontoxic esters that mini-
mize gastrointestinal disturbances while maintaining the
useful anti-inflammatory and analgesic activities of the
drug.rsity for Science 9 (2015) 455–464
2.  Materials  and  methods
2.1.  Materials
Fourier transform infrared spectra were recorded
as KBr pellets on a Perkin-Elmer 1600 spectropho-
tometer (Perkin Elmer Inc., USA); mass spectra were
recorded on a Jeol SX-102 instrument (Jeol Ltd, Tokyo,
Japan); and 1H nuclear magnetic resonance spectra
were recorded with CD3OD as solvent on a Brucker
DRX-300 spectrometer (Brucker BioSpin, Germany) at
300 MHz. Chemical shifts (δ) are given in ppm and
coupling constants (J) in Hz. Chemical shifts were refer-
enced to the residual solvent signal (CD3OD: δH = 3.30,
δC = 49.0). Trimethylsilyl was used as the internal
standard. Thin-layer chromatography was performed on
silica gel plates (Merck, Germany) with a mixture of
either chloroform:methanol:ammonia (5:2:3, v/v/v) or
water:n-propanol in various ratios. Melting-points were
determined in open glass capillaries on a programmable
melting-point apparatus (DBK Instruments, India).
Sulindac bulk drug was purchased from Aarti Drugs
Ltd, Mumbai, India. All the amino acids used were pur-
chased from Loba Chemie Pvt. Ltd, Mumbai, India.
All other chemicals and reagents used were of analyt-
ical grade and purchased from S.D. Fine Chem., Ltd,
Mumbai, India or Merck (India) Ltd, Mumbai, India.
2.2.  Animals
Albino Wistar rats (150–200 g) of each sex were
housed in polypropylene cages under standard condi-
tions of humidity (55 ±  5%), temperature (25 ±  2 ◦C), a
12 h/12 h light/dark cycle and access to food and water ad
libitum. Experiments were conducted in accordance with
the internationally accepted principles for laboratory ani-
mal use and care as per the United States guidelines (NIH
publication #85-23, revised in 1985).
2.3.  Synthesis  of  amino  acid  conjugates  of  sulindac
Sulindac (1.78 g, 0.005 mol/L) was dissolved in a
minimum amount of chloroform, and thionyl chloride
(0.5 mL) was added slowly. The mixture was refluxed for
6–7 h at 60–70 ◦C with continuous stirring on a magnetic
stirrer. The viscous liquid obtained was immediately
poured onto a Petri dish and dried to give crude sulindac
acid chloride (i). Thionyl chloride (0.5 mL) was added6–7 h at 60–70 ◦C with continuous stirring on a mag-
netic stirrer. The resulting solid was collected, dried and
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Table 1
Synthesized conjugates of sulindac.
Code IUPAC name R
SM1 Methyl 2-(2-((7Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-inden-3-
yl)acetamido)-3-phenylpropanoate
SM2 Methyl 2-(2-((1Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-inden-3-
yl)acetamido)-6
aminohexanoate
SM3 Methyl 2-(2((6Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-inden-3-
yl)acetamido)-5-guanidinopentanoate
SM4 Methyl 2-(2((6Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-inden-3-
yl)acetamido)acetate
CH
SM5 Methyl 2-(2((6Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-inden-3-
mercaptopropanoate
SM6 Methyl 2-(2((6Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-inden-3-
yl)acetamido)-3-methylbutanoate
SM7 Methyl 4-(2((6Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-inden-3-
yl)acetylcarbamoyl)-2-aminobutanoate
SM8 Methyl 2-(2((6Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-inden-3-
yl)acetamido)-3-hydroxypropanoate
SM9 Methyl 2-(2((6Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-inden-3-
yl)acetamido)-4-(methylthio)buatnoate
SM10 Methyl 2-(3Z)-3-(4-(methylsulfinyl)benzlidene)-6-fluoro-2-methyl-3H-inden-1-
carboxamido)propanoate
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re-crystallized from hot methanol, followed by cool-
ing. The purified crystals were collected and washed
twice with a 5:1 mixture of ether:methanol (v/v), then
with pure ether and dried to obtain pure amino acid
methyl ester hydrochloride (ii). Ice-cold aqueous sodium
hydroxide solution (5%, 5 mL) was taken up in a 250-
mL beaker, and the methyl ester hydrochloride of amino
acid (0.005 mol/L) was added. The reaction mixture was
stirred mechanically for 30 min at room temperature
and then in an ice bath. Sulindac acid chloride (1.78 g,
0.005 mol/L) was added in small portions and stirred
continuously for 6–7 h. The solid that separated out was
filtered off, and the crude conjugate was re-crystallized
from methanol (iii) (Scheme 1, Table 1) [6,7].
2.4.  Characterization  of  the  synthesized  conjugates
2.4.1.  Solubility
Approximately 10 mg of each conjugate was dis-
solved in 0.1 mL of each solvent at 37 ±  1 ◦C in glass
test tubes, which were then gently shaken until solubil-
ity was observed. If any insoluble fraction was observed,
a known amount of solvent was added to ascertain the
solubility of the conjugate.2.4.2.  Partition  coefﬁcient
A 20-mg aliquot of each conjugate was weighed and
dissolved in 20 mL chloroform. The solution was divided
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into two, and 10 mL acidic buffer (pH 1.2) and phos-
phate buffer (pH 7.4) were added separately to each.
The contents were thoroughly shaken for 24 h at room
temperature and then transferred to a separating funnel.
The chloroform layer was dried under high vacuum, and
the residue obtained was dissolved in methanol (10 mL);
20 L of this solution were further diluted to 1000 L
with methanol. An aliquot of 250 L was drawn from
this solution and mixed with 45 L of acidic buffer
(pH 1.2) or phosphate buffer (pH 7.4) and acetonitrile
solution in a ratio of 44:1. The volume was made to
1000 L by addition of methanol, and 20 L of this
solution were filtered and injected onto an HPLC col-
umn (C18 ODS reversed phase). The mobile phase was
acetonitrile:water (70:30). The peak areas of the drug
and the conjugates were observed at 284 nm in a photo-
diode array detector (SPD-10Avp, DAD with D2 lamp).
The purity of the synthesized conjugates was checked
by thin-layer chromatography. The plates of silica gel G
adsorbents were dried and activated. The solvent system
used for sulindac was chloroform:methanol:ammonia
(75:3:0.5). Iodine vapour was used as the detecting agent.
All conjugates were shown as single spots. The melting-
points of the synthesized conjugates were determined
in open capillary tubes in a melting-point apparatus
and are reported uncorrected. Infrared, nuclear mag-
netic resonance and mass spectra of the conjugates were
obtained [7].
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.5.  Biopharmaceutical  evaluation
.5.1.  Plasma–protein  binding
A solution of synthesized conjugate (20 g/mL) was
ade up in phosphate-buffered saline (PBS, pH 7.4), and
00 mL of this solution were taken in a beaker. The pre-
ared membrane was first washed with distilled water
nd then with buffer solution and tied to the opening of
 dialysis tube containing 6% egg albumin, which was
ipped into the drug solution and covered. The whole
ssembly was placed on a magnetic stirrer at low rev-
lutions per minute. The temperature was maintained
t 37 ±  0.5 ◦C. Every 2 h, 1 mL of the drug solution
as replaced with fresh PBS. The withdrawn sample
as diluted further with 1 mL phosphate buffer, and the
oncentration of conjugate was estimated on a spec-
rophotometer (Shimadzu UV-1601, Kyoto, Japan) [8].
.5.2. Dissolution  rate
The dissolution test apparatus (USPXXI) was
djusted to 100 rpm and 37 ◦C, and 100 mg of conju-
ate were suspended in 2 mL of simulated gastric fluid
SGF, pH 1.2) in a dialysis bag (cut off size, 5000) inside
he basket. The basket was dipped in 900 mL SGF, which
as kept in the internal jar of the dissolution test appa-
atus. Every 10 min, 5-mL samples were withdrawn and
eplaced with fresh SGF. The samples withdrawn from
he dissolution test apparatus were subjected to HPLC,
nd the peak area of the conjugates was observed at
84 nm with a UV detector. The samples of synthesized
onjugates and drug in SGF were not detected up to 2 h,
hich is considered the maximum time for a drug to
emain in the stomach; therefore, after 2 h, SGF was
eplaced by 900 mL of simulated intestinal fluid (SIF)
nd the dissolution test was run again at the same tem-
erature and speed [8].
.5.3. Hydrolytic  behaviour  of  synthesized
onjugates
The hydrolytic behaviour of the synthesized conju-
ates was studied in SGF (pH 1.2), SIF (pH 7.4) and
0% human plasma (pH 7.4). The hydrolysis rate of
ynthesized conjugates in SGF and SIF was studied by
reparing a solution of 10 mg of conjugate n  acetonitrile
2 mL), which was added to 88 mL of SIF (pH 7.4) or
GF (pH 1.2). Aliquots of 15 mL of this solution were
ithdrawn repeatedly and kept in test tubes maintained
t 37 ±  0.5 ◦C. At 15, 30, 45, 60, 75 and 90 min, an
liquot of 225 L was withdrawn from each test tube
nd transferred to micro-centrifuge tubes, with addition
f methanol to make up the volume. The tubes were
laced in a freezing mixture to arrest further hydrolysisrsity for Science 9 (2015) 455–464 459
and then vortexed at high speed for 5 min. After vortex-
ing, the tubes were centrifuged at 3000 rpm for 5 min.
The clear supernatant (20 L) obtained from each tube
was then injected onto the column of the HPLC instru-
ment, with a mobile phase of acetonitrile:water 70:30 at
a flow rate of 1 mL/min and a pressure of 120–135. The
retention times and peak areas were recorded for sulin-
dac conjugates in a photodiode array detector at 284 nm
[9].
The hydrolysis rate of synthesized conjugates in 80%
human plasma was studied by preparing a solution of
10 mg of conjugate in 2 mL acetonitrile and adding it
to 88 mL of 80% human plasma (pH 7.4), prepared by
mixing plasma with phosphate buffer pH 7.4 at a ratio of
80:20. Aliquots of 15 mL of this solution were drawn
and kept in test tubes maintained at 37 ±  0.5 ◦C. At
10, 20, 30, 40, 50 and 60 min, an aliquot of 225 L
was drawn from each tube and transferred to micro-
centrifuge tubes, which were placed in a freezing mixture
to arrest further hydrolysis, followed by vortexing at high
speed for 5 min. After vortexing, the tubes were cen-
trifuged at 6000 rpm for 5 min. The clear supernatant
(20 mL) obtained from each tube was injected onto the
HPLC column, with a mobile phase of acetonitrile:water
(70:30) was used for sulindac and conjugates. The reten-
tion times and peak areas were recorded for sulindac
conjugates in a photodiode array detector at 284 nm [10].
2.6.  Pharmacological  evaluation
2.6.1.  Analgesic  activity
The analgesic activity of the synthesized conjugates
was determined in rats by the tail flick reaction to a
thermal stimulus, the latency being assessed with an
analgesiometer (Medicraft Pvt. Ltd, Lucknow, India).
Twelve groups of six Wistar rats (150–200 g) were used
as control (vehicle-treated), standard (drug-treated) and
test (conjugate-treated) groups. Rats were placed in a
holder through which the tail protruded, and the time
taken to flick the tail was noted. The current was adjusted
so that more than 90% rats flicked their tails within
5–9 s. The drug or conjugate (3 mg/kg body weight) [11]
was administered orally in a 1% suspension of sodium
carboxymethylcellulose, and the reaction time was mea-
sured after 2 h; percentage analgesia was then calculated
for each animal [6,7]:
Percentage analgesia =
[
1 −
(
T2
T1
)]
×  100,where T1 is the reaction time in seconds before admin-
istration of the drug or conjugate, and T2 is the reaction
time in seconds after treatment.
h Unive
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2.6.2.  Anti-inﬂammatory  activity
The anti-inflammatory activity of the synthesized
conjugates was determined by the hind paw oedema
method with 0.1 mL of 1% carrageenan as the phlogistic
agent. The rats were divided into groups as described
above. The initial thickness of the right hind paw of each
rat was measured with a Vernier caliper, and then the
drug or conjugate was administered orally at 3 mg/kg
body weight [11] in 1% sodium carboxymethylcellulose
1 h before carrageenan injection. The zone of inflamma-
tion was measured 2 h later. The difference between the
two readings was taken as the measure of oedema. The
percentage anti-inflammatory activity was calculated
from [6,7]:
Percentage anti-inflammatory activity =  [1−(Vt−Vc)]
×100,
where Vc is the mean relative change in the thickness
of the right hind paw of control rats, and Vt is the mean
relative change in rats in the test group.
2.6.3. Acute  ulcerogenesis
The gastrointestinal toxicity of the synthesized conju-
gates was measured and compared with that of the drug
by measuring the ulcer index. The rats were divided into
groups as described above and fasted overnight. The drug
or conjugate (3 mg/kg body weight) was administered
orally in 1% sodium carboxymethylcellulose [11]. Eight
hours after treatment, the rats were sacrificed by decap-
itation and the stomach was extracted and dipped in 1%
formaldehyde solution for about 15 min and then cut out
along its great curvature. Lesions on the gastric mucosa
were counted by visual examination under a microscope.
Ulceration was scored as no ulcer (0), spot ulcer (1),
deep ulcer (2) or perforation (3), and the total score was
designated the ‘ulcer index’ [6,7,12], calculated from:
1 ×  (number of lesions of score 1) +  2 ×  (number of l
2.7.  Statistical  analysis
The results are expressed as mean ±  standard error
of the mean for each group. Statistical differences were
evaluated by one-way analysis of variance followed by
Dunnett’s test. Differences were considered to be statis-
tically significant at p  < 0.05.
3.  Results  and  discussionThe reaction used for synthesis is shown in
Scheme 1. Conjugates with 10 amino acids, phenyl-
alanine (SM1), lysine (SM2), arginine (SM3), glycinersity for Science 9 (2015) 455–464
 of score 2) +  3 ×  (number of lesions of score 3)
.
(SM4), cysteine (SM5), valine (SM6), glutamine
(SM7), serine (SM8), methionine (SM9) and ala-
nine (SM10), were synthesized (Scheme 1, Table 1).
In order to prepare the conjugates, sulindac acid
chloride (2,3,4-(methylsulfinyl)benzylidene)-6-fluoro-
2-methyl-3H-inden-1-yl)acetyl chloride (i) was pre-
pared as the precursor, and conjugates were provided
(iii) by reaction between sulindac acid chloride (i)
and the methyl esters of the amino acids (ii). The
physical constants of the conjugates are shown in
Table 2.
The synthesized conjugates were characterized on the
basis of their melting-points, thin-layer chromatography
(Table 2) and Fourier transform infrared, 1H nuclear
magnetic resonance and mass spectroscopy (Table 3),
and their solubility, partition coefficients, plasma-protein
binding, dissolution rates and hydrolytic rates were
determined.
Only sulindac was highly soluble in 0.1 N NaOH,
while the conjugates were slightly soluble. The drug
and all conjugates were insoluble in water and in
0.1 N HCl but showed moderate-to-high solubility in
methanol, ethanol, chloroform, dichloromethane and
benzene. Sulindac is more soluble mainly because of the
presence of a free carboxyl group, which forms a sodium
salt and makes the compound ionic. The moderate-to-
high solubility of the drug and conjugates in organic
solvents indicates that they are lipophilic.
The partition coefficient of the drug in CHCl3-PBS
(pH 7.4) was 7.04; those of SM1, SM3, SM4, SM9 and
SM10 were 12.78, 14.61, 15.32, 17.22 and 18.28; and
those of SM2, SM5, SM6, SM7 and SM8 were 20.42,
22.28, 21.02, 24.06 and 22.72. The partition coeffi-
cient of sulindac in CHCl3-acidic buffer (pH 1.4) was
76.62; those of SM1, SM3, SM4, SM9 and SM10 were
216.22, 254.32, 248.36, 332.22 and 321.15; and those of
SM2, SM5, SM6, SM7 and SM8 were 428.84, 506.02,
382.12, 642.22 and 654.62. These results indicate that
the conjugates partitioned towards the organic phase,
with enhanced lipophilicity, which might favour biolog-
ical absorption.
The phenomena of complex formation of proteins
with blood plasma is called as protein binding of drugs.
The less bound a drug is, the more efficiently it can
transverse from cell membrane.
The conjugates showed no dissolution in SGF, which
might minimize gastrointestinal disturbances but at
the same time would retard absorption, negating the
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Table 2
Physical constants of synthesized conjugates of sulindac.
Code Molecular formula Calculated
molecular mass
Melting-point (◦C) Yield (%) Colour Rf value % Nitrogen
Found Calculated
SM1 C30H28FNO4S 517.6 161–163 72 Yellowish white 0.77a 2.67 2.70
SM2 C27H31FN2O4S 498.6 114–116 57 Dirty white 0.63b 5.63 5.61
SM3 C27H31FN4O4S 526.6 131–133 66 Light yellow 0.63a 10.59 10.63
SM4 C23H22FNO4S 427.4 128–130 58 Light yellow 0.81a 3.29 3.27
SM5 C24H24FNO4S2 473.5 109–111 46 White 0.84b 2.92 2.95
SM6 C26H28FNO4S 469.6 122–124 68 Creamy white 0.69a 2.97 2.98
SM7 C26H27FN2O5S 498.5 157–159 67 Creamy white 0.86b 5.62 5.61
SM8 C24H24FNO5S 457.6 144–146 62 Dirty white 0.78b 3.08 3.06
SM9 C26H28FNO4S2 501.6 105–107 62 Light yellow 0.68a 2.78 2.79
SM10 C23H22FNO4S 427.4 104–106 73 Dirty white 0.74b 3.25 3.27
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Selting points are uncorrected.
a Solvent system: chloroform:methanol:ammonia (5:2:3).
b Solvent system: water:n-propanol (5:5).
ostulated higher absorption due to their high partition
oefficients. The conjugates had lower dissolution rates
han sulindac because of enhanced lipophilicity in SIF
ut high enough for easy absorption. Conjugates SM1,
M5 and SM6 were dissolved by more than 25% in 2 h.
he dissolution profiles of the synthesized conjugates of
ulindac are shown in Fig. 2.
In the studies of hydrolysis in SGF (pH 1.2), SIF
pH 7.4) and 80% human plasma (pH 7.4), the t1/2 was
able 3
nfrared, 1H nuclear magnetic resonance (NMR) and mass spectral characteri
onjugate Characteristic peaks of infrared spectra (KBr, cm−1) 
M1 3290 ( NH stretching of amide), 2975 ( CH stretching),
1708 ( C O stretching of ester), 1651 ( CONH2 amide)
1371 ( CH bend aliphatic)
M2 3866 ( NH stretching of amide), 2885 ( CH stretching),
1697 ( C O stretching of ester), 1651 ( CONH2 amide)
M3 3846 ( NH stretching of amide), 2885 ( CH stretching),
1697 ( C O stretching of ester), 1651 ( CONH2 amide)
M4 3388 ( NH stretching of amide), 3070 ( CH stretching),
1599 ( C O stretching of ester), 1560 ( CONH2 amide)
M5 3860 ( NH stretching of amide), 2925 ( CH stretching),
1699 ( C O stretching of ester), 1585 ( CONH2 amide)
M6 3065 ( NH stretching of amide), 2985 ( CH stretching),
1697 ( C O stretching of ester), 1651 ( CONH2 amide)
M7 3740 ( NH stretching of amide), 2980 ( CH stretching),
1699 ( C O stretching of ester), 1599 ( CONH2 amide)
M8 3460 ( NH stretching of amide), 3065 ( CH stretching),
1697 ( C O stretching of ester), 1597 ( CONH2 amide)
M9 3483 ( NH stretching of amide), 2978 ( CH stretching),
1699 ( C O stretching of ester), 1656 ( CONH2 amide)
M10 3508 ( NH stretching of amide), 2729 ( CH stretching),
1705 ( C O stretching of ester), 1651 ( CONH2 amide)180 min for SM4 was found as 180, 150–160 min for
SM1, SM3, SM5, SM6 and SM8 and 136–148 min for
SM2, SM7, SM9 and SM10. The pattern of hydrolysis in
SIF is shown in Fig. 3.
In 80% human plasma, the t1/2 values were 64 and
54 min for SM7 and SM5, 54 and 52 min for SM1 and
SM3, 37–45 min for SM2, SM6 and SM4 and 26–33 min
for SM10, SM8 and SM9. The pattern of hydrolysis in
80% human plasma is shown in Fig. 4.
zation of synthesized conjugates of sulindac.
Characteristic peaks of 1H NMR and mass spectra
(300 MHz, DMSO-d6, δ/ppm)
,
8.0 (NH), 7.08–7.12 (m, 5H), 6.85–7.65 (m, 7H), 4.81 (q,
CH, OCH3), 3.29–3.04 (q, 2H, CH2), 2.85 (t, 2H), 2.64 (s,
3H), 1.71 (d, 3H, OCH3); Found: M++1, 517.1
8 (NH), 6.85–7.65 (m, 7H), 2.85 (t, CH2), 2.65 (d, 2H), 2.64
(d, 3H), 2 (NH2), 1.90 (t, 2H), 1.55 (s, 2H), 1.29 (s, 2H);
Found: M++1, 498.0
8 (NH), 6.85–7.65 (m, 7H), 3.67 (d, 2H, OCH3), 2.85 (t,
CH2), 2.65 (d, 2H), 2.64 (d, 3H), 2.0 (NH2), 1.90 (t, 2H),
1.55 (s, 2H), 1.29 (s, 2H); Found: M++1, 526.0
8 (NH), 6.85–7.65 (m, 7H,), 4.16 (t, CH2), 3.67 (d, 3H),
2.85 (t, CH2), 2.64 (d, 3H); Found: M++1, 427.1
8 (NH), 6.85–7.65 (m, 7H,), 4.74 (q, CH), 4.16 (t, CH2),
3.67 (d, 3H), 2.85 (t, CH2), 1.50 (SH); Found: M++1, 473.4
8 (NH), 6.85–7.65 (m, 7H), 2.85 (t, CH2), 1.01 (m, 3H);
Found: M++1, 469.4.
10 (NH), 6.85–7.65 (m, 7H), 3.67 (d, 3H), 2.85 (t, CH2);
Found: M++1, 498.4
8 (NH), 6.85–7.65 (m, 7H), 2.85 (t, CH2), 2 (OH); Found:
M++1, 457.4
8 (NH), 6.85–7.65 (m, 7H), 4.16 (t, CH2), 3.67 (d, 3H), 2.85
(t, CH2), 2.64 (d, 3H); Found: M++1, 501.2.
8.0 (NH), 6.85–7.65 (m, 7H), 2.85 (t, CH2), 1.01 (m, 3H);
Found: M++1, 427.2
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Fig. 2. Dissolution profiles of synthesized conjugates of sulindac.
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The amount of sulindac regenerated on hydroly-
sis in SIF was 21.4% and 19.1%, respectively, for
SM8 and SM5, 12.4–16.2% for SM4, SM7, SM10 and
SM1 and 4.9–8.2% for SM2, SM6, SM3 and SM9.
The amount of sulindac regenerated on hydrolysis
in 80% human plasma was 62.2–63.3% for SM2,
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Fig. 4. Pattern of hydrolysis of synthesized conju of sulindac in simulated intestinal fluid pH 7.4.
SM3 and SM4, 51.2–54.1% for SM7, SM9, SM8
and SM1 and 30.6–38.3% for SM6, SM5 and SM10.
None of conjugates was hydrolysed in SGF, while
satisfactory hydrolysis was observed in SIF. All the con-
jugates showed encouraging hydrolysis rates in human
plasma.
)
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gates of sulindac in 80% human plasma.
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Table 4
Biological characteristics of synthesized amino acid conjugates of sulindac.
Group Treatment Analgesia (%) Anti-inflammatory activity (%) Ulcer index
Control Vehicle – – –
Standard Sulindac 59.62 ± 1.37 63.24 ± 1.46 21.75 ± 2.73
Treated
SM1 81.46 ± 2.05** 69.54 ± 0.91* 4.37 ± 0.76**
SM2 74.20 ± 2.32** 61.92 ± 1.70 7.13 ± 1.83**
SM3 49.18 ± 1.59** 55.31 ± 0.92** 4.56 ± 0.92**
SM4 19.31 ± 1.96** 59.23 ± 0.87ns 4.13 ± 0.64**
SM5 53.72 ± 1.84 41.29 ± 0.59** 5.53 ± 0.28**
SM6 84.24 ± 1.74** 71.22 ± 1.40** 5.24 ± 0.97**
SM7 68.42 ± 2.61** 60.48 ± 1.81ns 6.20 ± 1.13**
SM8 55.36 ± 0.78 53.16 ± 1.14** 4.72 ± 0.35**
SM9 71.14 ± 1.53** 67.37 ± 0.97ns 5.37 ± 1.07**
SM10 57.46 ± 1.02 58.20 ± 1.93ns 3.42 ± 0.72**
t
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(
t
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d* p < 0.05.
** p < 0.01 when compared with standard.
The analgesic activity of sulindac was found out
o be 59.6%. The synthesized conjugates SM1, SM2,
M6, SM7 and SM9 showed potent analgesic activity
68–84%), which was significantly (p  < 0.01) greater
han that of sulindac. The analgesic potential of con-
ugates SM5, SM8 and SM10 (53–58%) was not
ignificantly different from that of sulindac, while that of
M3 and SM4, 49% and 19.3%, was significantly lower.
The anti-inflammatory activity of sulindac was
3.2%; that of conjugates SM1 and SM6 was 69.5% and
1.2%, respectively, which are significantly greater than
hat of sulindac. Conjugates SM2, SM4, SM7, SM9 and
M10 showed similar (58–68%) and SM3, SM5 and SM8
howed significantly lower (41–55%) anti-inflammatory
ctivity than sulindac. The mean ulcer indexes of the
onjugates were significantly lower (3–7) than that of
ulindac (21.8).
The results (Table 4) indicate that conjugates SM1
nd SM6 have excellent pharmacological profiles, with
ignificantly increased analgesic and anti-inflammatory
ctivities and reduced ulcerogenesis.
Characterization of the conjugates established that
hey were in pure form and had the expected proper-
ies. The spectroscopic data suggest formation of the
esired compounds. The increased analgesic and anti-
nflammatory activities of the conjugates might be due
o various factors. The ulcer index of the conjugates was
uch lower than that of the standard drug. The formation
f amino acid conjugates of sulindac results in masking
f the carboxyl group of the drug moiety. Therefore, the
inimized side-effects of the conjugates might be dueo inhibition of direct contact of the carboxyl group with
he gastric mucosa, which is the mainly cause of gastric
amage [9,13,14].4.  Conclusion
A simple method has been developed for syn-
thesizing amino acid conjugates of sulindac. Amide
conjugation showed a synergistic potentiating effect,
with less disruption of mucosal surfaces. We conclude
that the conjugate approach can be used to minimize
gastrointestinal toxicity with no loss of the desired
anti-inflammatory and analgesic activities of the drug.
Conjugates SM1 and SM6 (methyl 2-(2-((7Z)-1-(4-
(methylsulfinyl)benzlidene)-5-fluoro-2-methyl-1H-
inden-3-yl)acetamido)-3-phenylpropanoate and methyl
2-(2((6Z)-1-(4-(methylsulfinyl)benzlidene)-5-fluoro-2-
methyl-1H-inden-3-yl)acetamido)-3-methylbutanoate)
showed the best pharmacological responses and
encouraging hydrolysis rates in both SIF and 80%
human plasma, with enhanced partition coefficients but
diminished dissolution and hydrolysis rates.
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